)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Wave Life Sciences
Wave Life Sciences (WVE) investor relations material
Wave Life Sciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
Q3 revenue was $13.2M, primarily from the GSK collaboration; lead programs target obesity (WVE-007), AATD (WVE-006) and PNPLA3-related liver disease (WVE-008).
Proprietary siRNA and RNA-editing capabilities advanced; GSK selected an siRNA development candidate, with three other collaboration programs progressing toward candidate selection.
Financial highlights
Q3 revenue was $13.2M vs. $7.6M YoY; operating expenses were $79.2M vs. $64.0M, including R&D of $53.8M vs. $45.9M and G&A of $25.4M vs. $18.1M.
Q3 net loss was $61.9M vs. $53.9M YoY; 9M net loss was $157.4M vs. $151.2M.
9M revenue was $53.7M vs. $25.5M, including a $12.0M GSK milestone and $35.9M of deferred AATD revenue recognized after license termination.
9M R&D was $152.6M vs. $130.0M; G&A was $72.2M vs. $54.4M, with increases primarily tied to compensation-related and other external expenses.
Outlook and guidance
WVE-007 600-mg single-dose Phase I data and WVE-006 600-mg monthly multidose data were expected in Q4 2026.
WVE-007 post-incretin maintenance trial initiation was targeted for Q4 2026; Phase II-A monotherapy and tirzepatide combination studies are underway.
FDA alignment supports planning a two-year WVE-006 registrational trial with a one-year interim analysis intended to support potential accelerated approval based on AATD biomarkers.
WVE-008 CTA submission was targeted for Q4 2026; first-in-human plans include circulating biomarkers and non-invasive liver imaging.
Cash resources were expected to fund operations into Q3 2028; this runway excludes potential future GSK collaboration payments.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Wave Life Sciences
- INHBE pairs durable fat-loss potential with lean-mass preservation; AAT editing advances toward registration.WVE
Chardan's 10th Annual Healthcare Conference - Shareholders face director, auditor, pay, and 11M-share plan votes after redomiciliation.WVEProxy filing
- Durable RNA editing and innovative obesity trials drive clinical and regulatory progress in 2024.WVE12th Annual Cantor Fitzgerald Global Healthcare Conference
- Advancing RNAi and RNA editing therapies with durable efficacy and infrequent dosing.WVECorporate presentation
- INHBE and WVE-006 advance with strong clinical data, regulatory momentum, and strategic interest.WVECanaccord Genuity's 46th Annual Growth Conference
- WVE-007 and AATD programs are set for major clinical and regulatory milestones in the coming year.WVEBank of America SMID Cap Virtual Conference
- Q2 2026 revenue dropped, net loss widened, but pipeline progress and cash runway remain strong.WVEQ2 2026
- Cash doubled to $602.1M, net loss widened, and major clinical milestones expected in 2026.WVEQ4 2025
- Durable fat loss and muscle preservation with WVE-007, plus key milestones in 2024 and 2026.WVE44th Annual J.P. Morgan Healthcare Conference
Next Wave Life Sciences earnings date
R&D Day 20264 Nov, 2026
Wave Life Sciences
Next Wave Life Sciences earnings date
R&D Day 20264 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Wave Life Sciences Ltd. (WVE) is a biotechnology company leveraging its proprietary RNA medicines platform, PRISM, to develop transformative treatments for a range of genetic diseases. This platform enables the design, optimization, and production of novel stereopure oligonucleotides, aimed at correcting disease-causing mutations, modulating protein activity, and restoring functional protein production or reducing disease-promoting RNAs or proteins. Wave's diverse pipeline includes clinical programs targeting Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, Huntington's disease, and a preclinical program for obesity, among others. Their approach includes multiple RNA-targeting modalities such as editing, splicing, RNA interference, and antisense silencing, showcasing their broad capabilities in addressing complex disease biology. The company is headquartered in Singapore, and its shares are listed on the Nasdaq.